HSC Section 6 Nov2016 Green Book

Otolaryngology–Head and Neck Surgery, Vol 139, No 3, September 2008

twice-daily esomeprazole treatment with a dose of 20 mg for three months demonstrated a significantly greater im- provement in laryngeal appearance and LPR-related symp- toms, as reflected by the total score differences of RFS and RSI. The most striking difference between the study groups was the significant reduction of posterior commissure hy- pertrophy in the PPI group. AUTHOR INFORMATION From the Department of Otorhinolaryngology–Head and Neck Surgery (Dr Reichel and Ms Wiederänders) and the Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine (Dr Dressel), Ludwig Maximilians University, Munich, Germany; and the Department of Oto- laryngology (Dr Issing), The Freeman Hospital, Newcastle Upon Tyne, UK. Corresponding author: Oliver Reichel, MD, Department of Otolaryngology– Head and Neck Surgery, Klinikum Großhadern, Marchioninistraße 15, 81377 Munich, Germany. E-mail address: Oliver.Reichel@med.uni-muenchen.de.

ing Disorders of the American Academy of Otolaryngology–Head and Neck Surgery. Otolaryngol Head Neck Surg 2002;127:32–5. 3. Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA 2005;294:1534–40. 4. Reichel O, Keller J, Rasp G, et al. Efficacy of once-daily esomeprazole treatment in patients with laryngopharyngeal reflux evaluated by 24- hour pH monitoring. Otolaryngol Head Neck Surg 2007;136:205–10. 5. Karkos PD, Wilson JA. Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systemativ review. Laryngoscope 2006; 116:144–8. 6. Havas T, Huang S, Levy M, et al. Posterior pharyngolaryngitis: dou- ble-blind, randomised placebo-controlled trial of proton pump inhibi- tor therapy. Aust J Otolaryngol 1999;3:243–6. 7. Steward DL, Wilson KM, Kelly DH, et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg 2004;131:342–50. 8. Wo JM, Koopman J, Harrell SP, et al. Double-blind, placebo-con- trolled trial with single-dose pantoprazole for laryngopharyngeal re- flux. Am J Gastroenterol 2006;101:1972–8. 9. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic pos- terior laryngitis with esomeprazole. Laryngoscope 2006;116:254–60. 10. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esome- prazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616–20. 11. Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). Laryngoscope 2001;111:1313–7. 12. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the Reflux Symptom Index (RSI). J Voice 2002;16:274–7. 13. Noordzij JP, Khidr A, Evans BA, et al. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope 2001;111:2147–51. 14. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991;101(suppl 53):1–78. 15. Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of posterior laryngitis. Am J Med 1994;96:321–6. 16. Eherer AJ, Habermann W, Hammer HF, et al. Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. Scand J Gastroenterol 2003;38:462–7. 17. Belafsky PC, Postma GN, Koufman JA. Laryngopharyngeal reflux symptoms improve before changes in physical findings. Laryngoscope 2001;111:979–81. 18. El-Serag HB, Lee P, Buchner A, et al. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol 2001;96:979–83. 19. Book DT, Rhee JS, Toohill RJ, et al. Perspectives in laryngopharyn- geal reflux: an international survey. Laryngoscope 2002;112:1399– 406. 20. DelGaudio JM, Waring JP. Empiric esomeprazole in the treatment of laryngopharyngeal reflux. Laryngoscope 2003;113:598–601.

AUTHOR CONTRIBUTIONS Oliver Reichel , study design, data collection; Holger Dressel , data anal- ysis, statistical analysis; Katrin Wiederänders , data collection; Wolfgang J. Issing , study design.

FINANCIAL DISCLOSURE This study was partially supported by a grant from Astra-Zeneca, Wedel, Germany. AstraZeneca had no involvement in the study design, collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

REFERENCES

1. Altman KW, Stephens RM, Lyttle CS, et al. Changing impact of gastroesophageal reflux in medical and otolaryngology practice. La- ryngoscope 2005;115:1145–53. 2. Koufman JA, Aviv JE, Casiano RR, et al. Laryngopharyngeal reflux: position statement of the Committee on Speech, Voice, and Swallow-

151